A Phase 1 interventional study of TV-46046 and Depo-subQ 104 in Contraception, sponsored by Teva Branded Pharmaceutical Products R&D, Inc.. Completed at 1 site in Dominican Republic. Open to female participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-01-26.
Sponsored by Teva Branded Pharmaceutical Products R&D, Inc. (part of Teva Pharmaceutical Industries, Ltd.) · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to evaluate the local tolerability associated with the SC administration of TV-46046, and inform next steps of the TV-46046 development program.
Eligible participants will be enrolled and receive 1 of each of the 4 SC study injections in each abdominal quadrant approximately 1 hour apart: 120 milligrams (mg)/0.3 milliliter (mL) of TV-46046, 60 mg/0.3 mL of 1:1 saline diluted TV-46046, 0.3 mL of TV-46046 Placebo and 104 mg/0.65 mL Depo-subQ 104 per the assigned sequence.
Teva Branded Pharmaceutical Products R&D, Inc. is the lead sponsor of 206 studies on the registry; none are open to participants now.
Of its 49 completed or terminated interventional studies of FDA-regulated products, 47 (96%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participant has no skin disorders or skin allergies
Exclusion Criteria:
Participant has a plan to move to another location in the next 18 months
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive TV-46046 undiluted (120 mg/0.3 mL of 400 mg/mL) SC injection as a test formulation in a crossover design with the other 3 SC study drug injections. The 4 study drug injections will be administered approximately 1 hour apart.
Drug: TV-46046
Participants will receive TV-46046 saline-diluted (60 mg/0.3 mL of 200 mg/mL) SC injection as a test formulation in a crossover design with the other 3 SC study drug injections. The 4 study drug injections will be administered approximately 1 hour apart.
Drug: TV-46046
Participants will receive TV-46046 placebo (0.3 mL) SC injection in a crossover design with the other 3 SC study drug injections. The 4 study drug injections will be administered approximately 1 hour apart.
Drug: TV-46046 Placebo
Participants will receive Depo-subQ 104 (medroxyprogesterone acetate injectable suspension; 104 mg/0.65 mL) SC injection as a reference formulation in a crossover design with the other 3 SC study drug injections. The 4 study drug injections will be administered approximately 1 hour apart.
Drug: Depo-subQ 104
TV-46046 will be administered per dose and schedule specified in the arm.
Depo-subQ 104 will be administered per dose and schedule specified in the arm.
Also known as: Medroxyprogesterone acetate injectable suspension, Depo-subQ Provera 104®
TV-46046 Placebo will be administered per schedule specified in the arm.
Number of Participants With Injection Site Reactions (ISRs) (Excluding Injection Site Pain)
ISRs were assessed by self-reports and direct observation for each injection at least twice on the day of injection. ISRs included erythema (redness), swelling, pruritus (itching), bleeding, bruising, injection site discoloration (for example, hypopigmentation), or atrophy (that is, dimple).
Time frame: Day 0 (immediately after and 1 hour after the injection) up to Month 18
Injection Site Pain Score, as Assessed by Numerical Rating Scale (NRS)
Participants assessed their injection site pain using an 11-point NRS (0 = no pain at all; 10 = worst pain). Higher scores denote worse outcome.
Time frame: Day 0 (Immediately after and 1 hour after injection)
Participant's Perception of Pain, as Assessed by an Overall Ranking of the 4 Study Injections From Least to Most Painful
Each participant was asked to rank the injections according to overall pain from least (score = 1) to most (score = 4) painful. If a participant could not rank all of her injections from least to most painful or could not uniquely identify which injection was the most painful, then her responses were appropriately weighted across groups (for example, if a participant ranked all 4 treatments as equally most painful, then that participant contributed a score of 0.25 to each group when assessing the distribution of the most painful injection and in the event of a tie between 2 rankings, 0.5 was assigned to each tied ranking).
Time frame: Day 0 (1 hour after injection)
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
An adverse event (AE) was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. AEs were considered treatment emergent if (a) the onset occurred on or after the time of first injection or (b) an event had an onset prior to the first injection but increased in severity after administration of the injection. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.
Time frame: Day 0 up to Month 18
| Milestone | Overall Study |
|---|---|
| Started | 27 |
| Received at least 1 dose of study drug | 27 |
| Completed | 27 |
| Not completed | 0 |
ISRs were assessed by self-reports and direct observation for each injection at least twice on the day of injection. ISRs included erythema (redness), swelling, pruritus (itching), bleeding, bruising, injection site discoloration (for example, hypopigmentation), or atrophy (that is, dimple).
| Participants | TV-46046 Undiluted | TV-46046 Diluted | TV-46046 Placebo | Depo-subQ 104 |
|---|---|---|---|---|
| Number of Participants With Injection Site Reactions (ISRs) (Excluding Injection Site Pain) | 12 | 6 | 0 | 8 |
Participants assessed their injection site pain using an 11-point NRS (0 = no pain at all; 10 = worst pain). Higher scores denote worse outcome.
| units on a scale | TV-46046 Undiluted | TV-46046 Diluted | TV-46046 Placebo | Depo-subQ 104 |
|---|---|---|---|---|
| Immediately after injection | 2.1 ± 1.72 | 1.9 ± 1.46 | 3.3 ± 2.15 | 1.2 ± 1.40 |
| 1 hour after injection | 0.2 ± 0.50 | 0.2 ± 0.50 | 0.6 ± 1.00 | 0.1 ± 0.29 |
Each participant was asked to rank the injections according to overall pain from least (score = 1) to most (score = 4) painful. If a participant could not rank all of her injections from least to most painful or could not uniquely identify which injection was the most painful, then her responses were appropriately weighted across groups (for example, if a participant ranked all 4 treatments as equally most painful, then that participant contributed a score of 0.25 to each group when assessing the distribution of the most painful injection and in the event of a tie between 2 rankings, 0.5 was assigned to each tied ranking).
| frequency (number of times) of ranking | TV-46046 Undiluted | TV-46046 Diluted | TV-46046 Placebo | Depo-subQ 104 |
|---|---|---|---|---|
| Pain Rank 1 | 4 | 5 | 4 | 9 |
| Pain Rank 2 | 8.5 | 8.5 | 0 | 5 |
| Pain Rank 3 | 4.5 | 4.5 | 6 | 7 |
| Pain Rank 4 | 5 | 4 | 12 | 1 |
An adverse event (AE) was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. AEs were considered treatment emergent if (a) the onset occurred on or after the time of first injection or (b) an event had an onset prior to the first injection but increased in severity after administration of the injection. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.
| Participants | Overall Study |
|---|---|
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | 23 |
Collected over Day 0 up to Month 18. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Follow-up After Treatment | 0/27 (0%) | 1/27 (3.7%) | 18/27 (66.7%) |
| TV-46046 Undiluted | 0/27 (0%) | 0/27 (0%) | 0/27 (0%) |
| TV-46046 Diluted | 0/27 (0%) | 0/27 (0%) | 1/27 (3.7%) |
| TV-46046 Placebo | 0/27 (0%) | 0/27 (0%) | 2/27 (7.4%) |
| Depo-subQ 104 | 0/27 (0%) | 0/27 (0%) | 0/27 (0%) |
| Event | Follow-up After Treatment | TV-46046 Undiluted | TV-46046 Diluted | TV-46046 Placebo | Depo-subQ 104 |
|---|---|---|---|---|---|
| CholelithiasisHepatobiliary disorders | 1/27 | 0/27 | 0/27 | 0/27 | 0/27 |
| Event | Follow-up After Treatment | TV-46046 Undiluted | TV-46046 Diluted | TV-46046 Placebo | Depo-subQ 104 |
|---|---|---|---|---|---|
| HeadacheNervous system disorders | 8/27 | 0/27 | 0/27 | 0/27 | 0/27 |
| AcarodermatitisInfections and infestations | 3/27 | 0/27 | 0/27 | 0/27 | 0/27 |
| InfluenzaInfections and infestations | 3/27 | 0/27 | 0/27 | 0/27 | 0/27 |
| Urinary tract infectionInfections and infestations | 3/27 | 0/27 | 0/27 | 0/27 | 0/27 |
| DizzinessNervous system disorders | 3/27 | 0/27 | 0/27 | 0/27 | 0/27 |
| Breast painReproductive system and breast disorders | 3/27 | 0/27 | 0/27 | 0/27 | 0/27 |
| Abdominal pain lowerGastrointestinal disorders | 2/27 | 0/27 | 0/27 | 0/27 | 0/27 |
| Injection site painGeneral disorders | 0/27 | 0/27 | 1/27 | 2/27 | 0/27 |
| VulvitisInfections and infestations | 2/27 | 0/27 | 0/27 | 0/27 | 0/27 |
| DysmenorrhoeaReproductive system and breast disorders | 2/27 | 0/27 | 0/27 | 0/27 | 0/27 |
The treated analysis set included all participants who received at least 1 of the 4 study drug injections.
| Age, Continuous(years) | Overall Study |
|---|---|
| Mean | 35.7 ± 6.20 |
| Sex: Female, Male(Participants) | Overall Study |
|---|---|
| Female | 27 |
| Male | 0 |
| Race/Ethnicity, Customized(Participants) | Overall Study |
|---|---|
| Race — Biracial | 26 |
| Race — Black or African American | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the study protocol and the statistical analysis plan. Requests will be reviewed for scientific merit, product approval status, and conflicts of interest. Patient level data will be de-identified and study documents will be redacted to protect the privacy of trial participants and to protect commercially confidential information. Please email USMedInfo@tevapharm.com to make your request.
Ran from Jan 2019 to primary completion in Oct 2020, 20 months.
Results were first posted in Jan 2022, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Medroxyprogesterone Acetate
Teva Branded Pharmaceutical Products R&D, Inc. →